Genprex, Inc. (GNPX) shareholders
Close on Nov 17, 2026Market cap $1.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GNPX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Fiduciary Trust Co | 3,550 | 0.43% | $40.54K | New | 0.00% |
| Hrt Financial LP | 3,276 | 0.40% | $37.00K | New | 0.00% |
| Geode Capital Management, LLC | 2,743 | 0.33% | $31.32K | +1,226 | 0.00% |
| Vanguard Capital Management LLC | 1,652 | 0.20% | $18.87K | +1,382 | 0.00% |
| Engineers Gate Manager LP | 949 | 0.12% | $10.84K | New | 0.00% |
| Mayflower Financial Advisors, LLC | 909 | 0.11% | $10.38K | – | 0.00% |
| UBS Group AG | 204 | 0.02% | $2.33K | +204 | 0.00% |
| Tower Research Capital LLC (TRC) | 129 | 0.02% | $1.48K | New | 0.00% |
| Barclays PLC | 72 | 0.01% | $819 | New | 0.00% |
| Jones Financial Companies Lllp | 55 | 0.01% | $597 | −41 | 0.00% |
| Cheviot Value Management, LLC | 45 | 0.01% | $519 | – | 0.00% |
| BlackRock, Inc. | 9 | 0.00% | $98 | – | 0.00% |
| Harbour Investments, Inc. | 5 | 0.00% | $56 | – | 0.00% |
| Osaic Holdings, Inc. | 4 | 0.00% | $41 | −7 | 0.00% |
| SBI Securities Co., Ltd. | 2 | 0.00% | $25 | – | 0.00% |
| Bernard Wealth Management Corp. | 1 | 0.00% | $16 | −8 | 0.00% |
| Integrated Wealth Concepts LLC | 1 | 0.00% | $11 | New | 0.00% |
| Allworth Financial LP | 1 | 0.00% | $12 | +1 | 0.00% |
| Caitong International Asset Management Co., Ltd | 0 | 0.00% | $1 | – | 0.00% |
| Capital Advisors, Ltd. LLC | 0 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 0M | 1.7% | 7 / 4 | 3 / 5 | 0M | 0M |
| Q1 2026 | 27 | 0M | 0.5% | 11 / 2 | 1 / 4 | 0M | 0M |
| Q4 2025 | 22 | 0M | 0.0% | 21 / 0 | 0 / 0 | 0M | 0M |
| Q3 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ryan M. Confer | President, CEO and CFO, Director | 36,331 | 4.43% | Feb 27, 2026 |
| Mark Stanley Berger | Chief Medical Officer | 21,692 | 2.65% | Feb 27, 2026 |
| Brent M. Longnecker | Director | 9,157 | 1.12% | Apr 15, 2026 |
| William R. Wilson Jr. | Director | 9,157 | 1.12% | Dec 23, 2025 |
| Toscano Jose Antonio Moreno | Director | 9,157 | 1.12% | Dec 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brent M. Longnecker Director | Apr 14, 2026 | Sale | −10 | $1.23 | $12 | 0 |
| Brent M. Longnecker Director | Apr 14, 2026 | Sale | −8 | $1.23 | $10 | 9,157 |
| Mark Stanley Berger Chief Medical Officer | Feb 27, 2026 | Tax withholding | −7,168 | $2.00 | $14.34K | 21,692 |
| Ryan M. Confer President, CEO and CFO, Director | Feb 27, 2026 | Tax withholding | −9,330 | $2.00 | $18.66K | 36,331 |
| Toscano Jose Antonio Moreno Director | Dec 22, 2025 | Award | +9,000 | – | – | 9,157 |
| Brent M. Longnecker Director | Dec 22, 2025 | Award | +9,000 | – | – | 9,165 |
| Ryan M. Confer President, CEO and CFO, Director | Dec 22, 2025 | Award | +45,000 | – | – | 45,661 |
| Mark Stanley Berger Chief Medical Officer | Dec 22, 2025 | Award | +28,500 | – | – | 28,860 |
| William R. Wilson Jr. Director | Dec 22, 2025 | Award | +9,000 | – | – | 9,157 |
| Ryan M. Confer President, CEO and CFO, Director | Jun 30, 2025 | Tax withholding | −5,775 | $0.23 | $1.33K | 32,968 |
| Mark Stanley Berger Chief Medical Officer | Jun 30, 2025 | Tax withholding | −4,500 | $0.23 | $1.04K | 17,971 |
| Mark Stanley Berger Chief Medical Officer | Feb 18, 2025 | Tax withholding | −585 | $0.41 | $240 | 22,471 |
| Ryan M. Confer President, CEO and CFO, Director | Feb 18, 2025 | Tax withholding | −395 | $0.41 | $162 | 38,743 |
| Ryan M. Confer President, CEO and CFO, Director | Dec 5, 2024 | Award | +29,375 | – | – | 39,138 |
| William R. Wilson Jr. Director | Dec 5, 2024 | Award | +4,750 | – | – | 7,845 |
| Brent M. Longnecker Director | Dec 5, 2024 | Award | +4,750 | – | – | 8,220 |
| Mark Stanley Berger Chief Medical Officer | Dec 5, 2024 | Award | +18,250 | – | – | 23,056 |
| Toscano Jose Antonio Moreno Director | Dec 5, 2024 | Award | +4,750 | – | – | 7,845 |
| Ryan M. Confer Chief Financial Officer | Feb 18, 2024 | Tax withholding | −1,126 | $4.40 | $4.95K | 9,763 |
| Mark Stanley Berger Chief Medical Officer | Feb 18, 2024 | Tax withholding | −1,319 | $4.40 | $5.80K | 4,806 |
| John Rodney Varner Chairman, President and CEO, Director | Feb 18, 2024 | Tax withholding | −2,642 | $4.40 | $11.62K | 26,352 |
| William R. Wilson Jr. Director | Jun 27, 2023 | Award | +123,795 | – | – | 123,795 |
| Toscano Jose Antonio Moreno Director | Jun 27, 2023 | Award | +123,795 | – | – | 123,795 |
| Brent M. Longnecker Director | Jun 27, 2023 | Award | +123,795 | – | – | 138,795 |
| John Rodney Varner Chairman, President and CEO, Director | Apr 21, 2023 | Buy | +19,000 | $1.06 | $20.14K | 20,800 |
| Catherine M. Vaczy EVP GC Chief Strategy Officer | Apr 21, 2023 | Buy | +20,000 | $1.07 | $21.40K | 265,000 |
| Mark Stanley Berger Chief Medical Officer | Feb 18, 2023 | Award | +245,000 | – | – | 245,000 |
| Hermant Kumar Chief Mfgr & Tech Officer | Feb 18, 2023 | Award | +200,000 | – | – | 200,000 |
| John Rodney Varner President & CEO, Director | Feb 18, 2023 | Award | +625,000 | – | – | 1,159,735 |
| Ryan M. Confer Chief Financial Officer | Feb 18, 2023 | Award | +245,000 | – | – | 435,499 |
| Catherine M. Vaczy EVP GC Chief Strategy Officer | Feb 18, 2023 | Award | +245,000 | – | – | 245,000 |
| Ryan M. Confer Chief Financial Officer | Jul 28, 2022 | Option exercise | +116,973 | $0.02 | $2.34K | 190,499 |
| John Rodney Varner President & CEO, Director | Jun 14, 2021 | Gift | −1,614,152 | – | – | 0 |
| Brent M. Longnecker Director | Apr 5, 2021 | Buy | +15,000 | $4.15 | $62.25K | 15,000 |
| John Rodney Varner Chief Executive Officer, Director, 10% owner | Sep 5, 2019 | Buy | +1,800 | $0.89 | $1.60K | 1,800 |
| Jack A. Roth 10% owner | Dec 5, 2018 | Other | −250,000 | – | – | 814,853 |
| Jack A. Roth 10% owner | Dec 5, 2018 | Other | −0 | – | – | 646,960 |
| Viet-An Hoan Ly 10% owner | Sep 27, 2018 | Other | −583,008 | – | – | 0 |
| Viet-An Hoan Ly 10% owner | Sep 27, 2018 | Other | −102,000 | – | – | 0 |
| Viet-An Hoan Ly 10% owner | Sep 27, 2018 | Other | −475,974 | – | – | 36,067 |
| Julien L. Pham President & COO | Jul 30, 2018 | Buy | +500 | $3.40 | $1.70K | 500 |
| Jack A. Roth 10% owner | Mar 29, 2018 | Buy | +40,000 | $5.00 | $200.00K | 1,338,999 |
| John Rodney Varner Chief Executive Officer, Director, 10% owner | Mar 29, 2018 | Buy | +10,000 | $5.00 | $50.00K | 544,735 |
| Christy M. Nance 10% owner | Mar 29, 2018 | Buy | +50,000 | $5.00 | $250.00K | 50,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Genprex's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,660 shares on Sep 24, 2026 over the last 90 days.
Congress trades
4 trades in Genprex reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Tim Moore NC14 | Bought | Feb 5, 2026 | $1K–15K | Feb 20, 2026 |
| Tim Moore NC14 | Bought | Dec 18, 2025 | $1K–15K | Jan 7, 2026 |
| Tim Moore NC14 | Bought | Nov 7, 2025 | $1K–15K | Dec 2, 2025 |
| Tim Moore NC14 | Bought | Oct 29, 2025 | $15K–50K | Nov 12, 2025 |
See a number that looks wrong?